ReP USP - Resultado da busca

Artigo de periodico
Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations (2024)
Ponnaiah, Maharajah; Zakiev, Emile; Lhomme, Marie; Rached, Fabiana; Camont, Laurent; Serrano Junior, Carlos Vicente ; Santos Filho, Raul Dias dos ; Chapman, M. John; Orekhov, Alexander; Kontush, Anatol
Source: ATHEROSCLEROSIS PLUS. Unidade: FM
Subjects: LIPOPROTEÍNAS LDL, INFARTO DO MIOCÁRDIO, FATORES DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PONNAIAH, Maharajah et al. Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations. ATHEROSCLEROSIS PLUS, v. 55, p. 21-30, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58815. Acesso em: 16 nov. 2024.
APA
Ponnaiah, M., Zakiev, E., Lhomme, M., Rached, F., Camont, L., Serrano Junior, C. V., et al. (2024). Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations. ATHEROSCLEROSIS PLUS, 55, 21-30. doi:10.1016/j.athplu.2023.12.001
NLM
Ponnaiah M, Zakiev E, Lhomme M, Rached F, Camont L, Serrano Junior CV, Santos Filho RD dos, Chapman MJ, Orekhov A, Kontush A. Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations [Internet]. ATHEROSCLEROSIS PLUS. 2024 ; 55 21-30.[citado 2024 nov. 16 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58815
Vancouver
Ponnaiah M, Zakiev E, Lhomme M, Rached F, Camont L, Serrano Junior CV, Santos Filho RD dos, Chapman MJ, Orekhov A, Kontush A. Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations [Internet]. ATHEROSCLEROSIS PLUS. 2024 ; 55 21-30.[citado 2024 nov. 16 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58815
Artigo de periodico-carta/editorial
Vaccine hesitancy in patients with autoimmune diseases. [Carta]: data from the coronavirus disease-2019 vaccination in autoimmune diseases study (2022)
Sen, Parikshit; Lilleker, James B; Agarwal, Vishwesh; Kardes, Sinan; Milchert, Marcin; Gheita, Tamer; Salim, Babur; Velikova, Tsvetelina; Gracia-Ramos, Abraham Edgar; Shinjo, Samuel Katsuyuki
Source: Indian journal of rheumatology. Unidade: FM
Subjects: DOENÇAS AUTOIMUNES, COVID-19, VACINAS VIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SEN, Parikshit et al. Vaccine hesitancy in patients with autoimmune diseases. [Carta]: data from the coronavirus disease-2019 vaccination in autoimmune diseases study. Indian journal of rheumatology. Mumbai: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.4103/injr.injr_221_21. Acesso em: 16 nov. 2024. , 2022
APA
Sen, P., Lilleker, J. B., Agarwal, V., Kardes, S., Milchert, M., Gheita, T., et al. (2022). Vaccine hesitancy in patients with autoimmune diseases. [Carta]: data from the coronavirus disease-2019 vaccination in autoimmune diseases study. Indian journal of rheumatology. Mumbai: Faculdade de Medicina, Universidade de São Paulo. doi:10.4103/injr.injr_221_21
NLM
Sen P, Lilleker JB, Agarwal V, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Shinjo SK. Vaccine hesitancy in patients with autoimmune diseases. [Carta]: data from the coronavirus disease-2019 vaccination in autoimmune diseases study [Internet]. Indian journal of rheumatology. 2022 ; 17( 2): 188-191.[citado 2024 nov. 16 ] Available from: https://doi.org/10.4103/injr.injr_221_21
Vancouver
Sen P, Lilleker JB, Agarwal V, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Shinjo SK. Vaccine hesitancy in patients with autoimmune diseases. [Carta]: data from the coronavirus disease-2019 vaccination in autoimmune diseases study [Internet]. Indian journal of rheumatology. 2022 ; 17( 2): 188-191.[citado 2024 nov. 16 ] Available from: https://doi.org/10.4103/injr.injr_221_21
Artigo de periodico
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease (2019)
Charytan, David M; Solomon, Scott D; Ivanovich, Peter; Remuzzi, Giuseppe; Cooper, Mark E; Mcgill, Janet B; Parving, Hans-Henrik; Parfrey, Patrick; Singh, Ajay K; Burdmann, Emmanuel de Almeida
Source: Diabetes obesity & metabolism. Unidade: FM
Subjects: DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, INSUFICIÊNCIA RENAL CRÔNICA, METFORMINA, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHARYTAN, David M et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes obesity & metabolism, v. 21, n. 5, p. 1199-1208, 2019Tradução . . Disponível em: https://doi.org/10.1111/dom.13642. Acesso em: 16 nov. 2024.
APA
Charytan, D. M., Solomon, S. D., Ivanovich, P., Remuzzi, G., Cooper, M. E., Mcgill, J. B., et al. (2019). Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes obesity & metabolism, 21( 5), 1199-1208. doi:10.1111/dom.13642
NLM
Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, Mcgill JB, Parving H-H, Parfrey P, Singh AK, Burdmann E de A. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease [Internet]. Diabetes obesity & metabolism. 2019 ; 21( 5): 1199-1208.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/dom.13642
Vancouver
Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, Mcgill JB, Parving H-H, Parfrey P, Singh AK, Burdmann E de A. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease [Internet]. Diabetes obesity & metabolism. 2019 ; 21( 5): 1199-1208.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/dom.13642
Artigo de periodico
Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT) (2019)
Causland, Finnian R. Mc; Claggett, Brian; Burdmann, Emmanuel de Almeida; Chertow, Glenn M; Cooper, Mark E; Eckardt, Kai-Uwe; Ivanovich, Peter; Levey, Andrew S; Lewis, Eldrin F; Mcgill, Janet B
Source: American journal of kidney diseases. Unidade: FM
Subjects: ANEMIA, ERITROPOIETINA, HEMODIÁLISE, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAUSLAND, Finnian R. Mc et al. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT). American journal of kidney diseases, v. 73, n. 3, p. 309-315, 2019Tradução . . Disponível em: https://doi.org/10.1053/j.ajkd.2018.10.006. Acesso em: 16 nov. 2024.
APA
Causland, F. R. M., Claggett, B., Burdmann, E. de A., Chertow, G. M., Cooper, M. E., Eckardt, K. -U., et al. (2019). Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT). American journal of kidney diseases, 73( 3), 309-315. doi:10.1053/j.ajkd.2018.10.006
NLM
Causland FRM, Claggett B, Burdmann E de A, Chertow GM, Cooper ME, Eckardt K-U, Ivanovich P, Levey AS, Lewis EF, Mcgill JB. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT) [Internet]. American journal of kidney diseases. 2019 ; 73( 3): 309-315.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1053/j.ajkd.2018.10.006
Vancouver
Causland FRM, Claggett B, Burdmann E de A, Chertow GM, Cooper ME, Eckardt K-U, Ivanovich P, Levey AS, Lewis EF, Mcgill JB. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT) [Internet]. American journal of kidney diseases. 2019 ; 73( 3): 309-315.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1053/j.ajkd.2018.10.006
Artigo de periodico
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes (2018)
Everett, Brendan M.; Nicolau, Jose C.; DONATH, Marc Y.; PRADHAN, Aruna D.; THUREN, Tom; PAIS, Prem; GLYNN, Robert J; LIBBY, Peter; RIDKER, Paul M.
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTI-INFLAMATÓRIOS, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EVERETT, Brendan M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, v. 71, n. 21, p. 2392-2401, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.03.002. Acesso em: 16 nov. 2024.
APA
Everett, B. M., Nicolau, J. C., DONATH, M. Y., PRADHAN, A. D., THUREN, T., PAIS, P., et al. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, 71( 21), 2392-2401. doi:10.1016/j.jacc.2018.03.002
NLM
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Vancouver
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Artigo de periodico
Consensus statement: osteoporosis prevention and treatment in Latin America-current structure and future directions (2018)
Albergaria, Ben-Hur; Chalem, Monique; Clark, Patricia; Messina, Osvaldo Daniel; Pereira, Rosa Maria Rodrigues; Vidal, Luis F.
Source: Archives of osteoporosis. Unidade: FM
Subjects: PRÁTICA CLÍNICA, OSTEOPOROSE, MENOPAUSA, PREVALÊNCIA, MULHERES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALBERGARIA, Ben-Hur et al. Consensus statement: osteoporosis prevention and treatment in Latin America-current structure and future directions. Archives of osteoporosis, v. 13, n. 1, 2018Tradução . . Disponível em: https://doi.org/10.1007/s11657-018-0505-x. Acesso em: 16 nov. 2024.
APA
Albergaria, B. -H., Chalem, M., Clark, P., Messina, O. D., Pereira, R. M. R., & Vidal, L. F. (2018). Consensus statement: osteoporosis prevention and treatment in Latin America-current structure and future directions. Archives of osteoporosis, 13( 1). doi:10.1007/s11657-018-0505-x
NLM
Albergaria B-H, Chalem M, Clark P, Messina OD, Pereira RMR, Vidal LF. Consensus statement: osteoporosis prevention and treatment in Latin America-current structure and future directions [Internet]. Archives of osteoporosis. 2018 ; 13( 1):[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s11657-018-0505-x
Vancouver
Albergaria B-H, Chalem M, Clark P, Messina OD, Pereira RMR, Vidal LF. Consensus statement: osteoporosis prevention and treatment in Latin America-current structure and future directions [Internet]. Archives of osteoporosis. 2018 ; 13( 1):[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s11657-018-0505-x
Artigo de periodico
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2018)
Giugliano, Robert P.; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIUGLIANO, Robert P. e NICOLAU, Jose Carlos. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, v. 137, n. 15, p. 1571-0, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.117.030950. Acesso em: 16 nov. 2024.
APA
Giugliano, R. P., & Nicolau, J. C. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137( 15), 1571-0. doi:10.1161/CIRCULATIONAHA.117.030950
NLM
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Vancouver
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Artigo de periodico
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract (2018)
Mach, Francois; Santos, Raul D
Source: European heart journal. Unidade: FM
Subjects: INSUFICIÊNCIA RENAL CRÔNICA, MORTALIDADE, DIABETES MELLITUS, ESTUDOS RANDOMIZADOS, PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACH, Francois e SANTOS, Raul D. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European heart journal, v. 39, n. 27, p. 2526-+, 2018Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehy182. Acesso em: 16 nov. 2024.
APA
Mach, F., & Santos, R. D. (2018). Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European heart journal, 39( 27), 2526-+. doi:10.1093/eurheartj/ehy182
NLM
Mach F, Santos RD. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract [Internet]. European heart journal. 2018 ; 39( 27): 2526-+.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1093/eurheartj/ehy182
Vancouver
Mach F, Santos RD. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract [Internet]. European heart journal. 2018 ; 39( 27): 2526-+.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1093/eurheartj/ehy182
Artigo de periodico
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) (2018)
Vallejo-vaz, Antonio J; Santos Filho, Raul Dias dos
Source: Atherosclerosis. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, COOPERAÇÃO INTERNACIONAL, MÉTODOS EPIDEMIOLÓGICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VALLEJO-VAZ, Antonio J e SANTOS FILHO, Raul Dias dos. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, v. 277, p. 234-255, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.atherosclerosis.2018.08.051. Acesso em: 16 nov. 2024.
APA
Vallejo-vaz, A. J., & Santos Filho, R. D. dos. (2018). Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 277, 234-255. doi:10.1016/j.atherosclerosis.2018.08.051
NLM
Vallejo-vaz AJ, Santos Filho RD dos. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) [Internet]. Atherosclerosis. 2018 ; 277 234-255.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2018.08.051
Vancouver
Vallejo-vaz AJ, Santos Filho RD dos. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) [Internet]. Atherosclerosis. 2018 ; 277 234-255.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2018.08.051
Artigo de periodico-carta/editorial
Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials [Editorial]: more data still necessary (2017)
Santos Filho, Raul Dias dos
Source: Current opinion in lipidology. Unidade: FM
Subjects: GENÉTICA MÉDICA, EPIDEMIOLOGIA, BIOLOGIA CELULAR, ESTUDOS RANDOMIZADOS, COLESTEROL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS FILHO, Raul Dias dos. Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials [Editorial]: more data still necessary. Current opinion in lipidology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1097/MOL.0000000000000460. Acesso em: 16 nov. 2024. , 2017
APA
Santos Filho, R. D. dos. (2017). Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials [Editorial]: more data still necessary. Current opinion in lipidology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. doi:10.1097/MOL.0000000000000460
NLM
Santos Filho RD dos. Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials [Editorial]: more data still necessary [Internet]. Current opinion in lipidology. 2017 ; 28( 6): 522-523.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1097/MOL.0000000000000460
Vancouver
Santos Filho RD dos. Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials [Editorial]: more data still necessary [Internet]. Current opinion in lipidology. 2017 ; 28( 6): 522-523.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1097/MOL.0000000000000460
Artigo de periodico
Familial hypercholesterolaemia (2017)
Defesche, Joep C.; Gidding, Samuel S.; Harada-Shiba, Mariko; Santos Filho, Raul Dias dos; Wierzbicki, Anthony S.
Source: Nature reviews disease primers. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, COLESTEROL, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DEFESCHE, Joep C. et al. Familial hypercholesterolaemia. Nature reviews disease primers, v. 3, 2017Tradução . . Disponível em: https://doi.org/10.1038/nrdp.2017.93. Acesso em: 16 nov. 2024.
APA
Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Santos Filho, R. D. dos, & Wierzbicki, A. S. (2017). Familial hypercholesterolaemia. Nature reviews disease primers, 3. doi:10.1038/nrdp.2017.93
NLM
Defesche JC, Gidding SS, Harada-Shiba M, Santos Filho RD dos, Wierzbicki AS. Familial hypercholesterolaemia [Internet]. Nature reviews disease primers. 2017 ; 3[citado 2024 nov. 16 ] Available from: https://doi.org/10.1038/nrdp.2017.93
Vancouver
Defesche JC, Gidding SS, Harada-Shiba M, Santos Filho RD dos, Wierzbicki AS. Familial hypercholesterolaemia [Internet]. Nature reviews disease primers. 2017 ; 3[citado 2024 nov. 16 ] Available from: https://doi.org/10.1038/nrdp.2017.93
Artigo de periodico
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD (2017)
Charytan, David M.; Burdmann, Emmanuel de Almeida
Source: American journal of kidney diseases. Unidade: FM
Subjects: FALÊNCIA RENAL CRÔNICA, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS, INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHARYTAN, David M. e BURDMANN, Emmanuel de Almeida. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, v. 70, n. 4, p. 522-531, 2017Tradução . . Disponível em: http://observatorio.fm.usp.br/handle/OPI/21785. Acesso em: 16 nov. 2024.
APA
Charytan, D. M., & Burdmann, E. de A. (2017). ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, 70( 4), 522-531. doi:10.1053/j.ajkd.2017.04.018
NLM
Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2024 nov. 16 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785
Vancouver
Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2024 nov. 16 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Source title

Funding Agencies